AbbVie To Submit European Application For Epcoritamab In Lymphoma Setting Later In 2022

Genmab A/S GMAB has announced that AbbVie Inc ABBV will submit a conditional marketing authorization application with the European Medicines Agency for subcutaneous epcoritamab (DuoBody-CD3xCD20) for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in 2H of 2022.
Epcoritamab is an investigational bispecific antibody.
Genmab recently announced that the company would submit a biologics license application (BLA) for epcoritamab with FDA for relapsed/refractory large B-cell lymphoma (LBCL), also in 2H of 2022.
Related: AbbVie - Genmab Present Epcoritamab Data From Lymphoma Trial.
The European submission is supported by results from the large b-cell lymphoma (LBCL) cohort of the pivotal EPCORE NHL-1 trial.
Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.
Price Action: ABBV shares are down 1.13% at $151.86, and GMAB is up 1.64% at $34.87 during the market session on the last check Monday.